These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17325698)

  • 1. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    Uramoto H; Mitsudomi T
    Br J Cancer; 2007 Mar; 96(6):857-63. PubMed ID: 17325698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
    Amler LC; Goddard AD; Hillan KJ
    Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Cappuzzo F
    Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    Pao W; Miller VA
    J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Rossi A; Pasquale R; Esposito C; Normanno N
    Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
    Taguchi F; Solomon B; Gregorc V; Roder H; Gray R; Kasahara K; Nishio M; Brahmer J; Spreafico A; Ludovini V; Massion PP; Dziadziuszko R; Schiller J; Grigorieva J; Tsypin M; Hunsucker SW; Caprioli R; Duncan MW; Hirsch FR; Bunn PA; Carbone DP
    J Natl Cancer Inst; 2007 Jun; 99(11):838-46. PubMed ID: 17551144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 17. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR FISH versus mutation: different tests, different end-points.
    Cappuzzo F
    Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
    Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
    Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.